Prospects for development of new antimycobacterial drugs

Journal of Infection and Chemotherapy

Volumn 6, Issue 1, 2000, Pages 8-20

  Tomioka, Haruaki ^a  

^a SHIMANE UNIVERSITY   (Japan)

Author keywords

Fluoroquinolones; Mcobacterium avium complex; Mycobacterial infection; Mycobacterium tuberculosis; New macrolides; Rifamycin

Indexed keywords

ANTIMYCOBACTERIAL AGENT; AZITHROMYCIN; CIPROFLOXACIN; CLARITHROMYCIN; GATIFLOXACIN; LEVOFLOXACIN; MACROLIDE; MOXIFLOXACIN; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFABUTIN; RIFALAZIL; RIFAMYCIN DERIVATIVE; RIFAPENTINE; ROXITHROMYCIN; SITAFLOXACIN; SPARFLOXACIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; DRUG ACTIVITY; DRUG EFFICACY; MULTIDRUG RESISTANCE; MYCOBACTERIOSIS; MYCOBACTERIUM AVIUM; MYCOBACTERIUM TUBERCULOSIS; REVIEW; TUBERCULOSIS;

EID: 0034012047     PISSN: 1341321X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s101560050043     Document Type: Review

References (148)

1. Kochi A, Vareldzis B, Styblo K. Multidrug-resistant tuberculosis and its control. Res Microbiol 1993;144:104-10.
2. McGowan JE. Multiple-drug-resistant tuberculosis: clinical and laboratory issues. Res Microbiol 1993;144:122-9.
3. Riley LW. Drug-resistant tuberculosis. Clin Infect Dis 1993; 17(Suppl 2):S442-6.
4. Hart CA, Beeching NJ, Duerden BI. Tuberculosis into the next centry. J Med Microbiol 1996;44:1-34.
5. Cohn DL, Iseman MD. Treatment and prevention of multidrug-resistant tuberculosis. Res Microbiol 1993;144:150-3.
6. Fischl MA, Uttamchadani RB, Daikos GL, Poblete RB, Moreno JN, Reyes RR, et al. An outbreak of tuberculosis caused by multiple-drug-resistant tubercle bacilli among patients with HIV infection. Ann Intern Med 1992;117:177-83.
7. Frieden TR, Sterling T, Pablos-Mendez A, Kilburn JO, Cauthen GM, Dooley SW. The emergence of drug-resistant tuberculosis in New York City. New Engl J Med 1993;328:521-6.
8. Snider DE, Cohn DL, Davidson PT, Hershfield ES, Smith MH, Sutton FD. Standard therapy for tuberculosis 1985. Chest 1985;87(Suppl):117S-24S.
9. Inderlied CB, Kemper CA, Bermudez LEM. The Mycobacterium avium complex. Clin Microbiol Rev 1993;6:266-310.
10. Falkinham JO. Epidemiology of infection by nontuberculous mycobacteria. Clin Microbiol Rev 1996;9:177-215.
11. Ellner JJ, Goldberger MJ, Parenti DM. Mycobacterium avium infection and AIDS: a therapeutic dilemma in rapid evolution. J Infect Dis 1991;163:1326-35.
12. Dauzenberg B. Clinical trials in Mycobacterium avium therapy: lessons to take home. Res Microbiol 1994;145:197-206.
13. Benson CA. Treatment of disseminated Mycobacterium avium complex disease: a clinician's perspective. Res Microbiol 1996;147:16-24.
14. Reyen CF, Pastel M, Arbeit RD. Clinical and epidemiologic implications of polyclonal infection due to Mycobacterium avium complex. Res Microbiol 1996;147:24-30.
15. Hooper DC, Wolfson JS. The fluoroquinolones: pharmacology, clinical uses, and toxicities. Antimicrob Agents Chemother 1985;28:716-21.
16. Leysen DC, Haemers A, Pattyn SR. Mycobacteria and the new quinolones. Antimicrob Agents Chemother 1989;33:1-5.
17. Yew WW, Chau CH. New antimycobacterial agents. Monaldi Arch Chest Dis 1996;51:394-404.
18. Alangaden GJ, Lerner SA. The clinical use of fluoroquinolones for the treatment of mycobacterial diseases. Clin Infect Dis 1997;25:1213-21.
19. Grassi C. New drugs for tuberculosis. Exp Opin Invest Drugs 1997;6:1211-26.
20. Tomioka H, Saito H, Sato K. Comparative antimycobacterial activities of the newly synthesized quinolone AM-1155, sparfloxacin, and ofloxacin. Antimicrob Agents Chemother 1993;37: 1259-63.
21. Saito H, Tomioka H, Sato K, Dekio S. In vitro and in vivo antimycobacterial activities of a new quinolone, DU-6859a. Antimicrob Agents Chemother 1994;38:2877-82.
22. Ji B, Lounis M, Maslo C, Truffot-Pernot C, Bonnafous P, Grosset J. In vitro and in vivo activities of moxifloxacin and clinafloxacin aoainst Mycobacterium tuberculosis. Antimicrob Agents Chemother 1998;42:2066-9.
23. Tomioka H, Sato K, Akaki T, Kajitani H, Kawahara S, Sakatani M. Comparative in vitro antimicrobial activities of the newly synthesized quinolone HSR-903, sitafloxacin (DU-6859a), gatifloxacin (AM-1155), and levofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex. Antimicrob Agents Chemother 1999;43:3001-4.
24. Heifets LB, Lindholm-Levy P. Bacteriostatic and bactericidal activity of ciprofloxacin and ofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex. Tubercle 1987;68: 267-76.
25. Gorzynski EA, Gutman SI, Allen W. Comparative antimycobacterial activities of difloxacin, temafloxacin, enoxacin, pefloxacin, reference fluoroquinolones, and a new macrolide, clarithromycin. Antimicrob Agents Chemother 1989;33:591-2.
26. Tomioka H, Sato K, Saito H. Comparative in vitro and in vivo activity of fleroxacin and ofloxacin against various mycobacteria. Tubercle 1991;72:176-80.
27. Garcia-Rodriguez JA, Garcia ACG. In-vitro activities of quinolones against mycobacteria. J Antimicrob Chemother 1993;32:797-808.
28. Ji B, Lounis N, Truffot-Pernot C, Grosset J. In vitro and in vivo activities of levofloxacin against Mycobacterium tuberculosis. Antimicrob Agents Chemother 1995;39:1341-4.
29. Saito H, Sato K, Tomioka H, Dekio S. In vitro antimycobacterial activity of a new quinolone, levofloxacin (DR-3355). Tuberc Lung Dis 1995;76:377-80.
30. Bermudez LE, Inderlied CB, Kolonoski P, Wu M, Barbara-Burnham L, Young LS. Activities of BAY 3118, levofloxacin, and ofloxacin alone or in combination with ethambutol against Mycobacterium avium complex in vitro, in human macrophages, and in beige mice. Antimicrob Agents Chemother 1996;40:546-51.
31. Herbert D, Paramasivan CN, Venkatesan P, Kubendiran G, Prabhakar R, Mitchinson DA. Bactericidal action of ofloxacin, sulbactam-ampicilin, rifampin, and isoniazid on logarithmic-and stationary-phase cultures of Mycobacterium tuberculosis. Antimicrob Agents Chemother 1996;40:2296-9.
32. Rastogi N, Labrousse V, Goh KS. In vitro activities of fourteen antimicrobial agents against drug susceptible and resistant clinical isolates of Mycobacterium tuberculosis and comparative intracellular activities against the virulent H37Rv strain in human macrophages. Curr Microbiol 1996;33:167-75.
33. Rastogi N, Goh KS, Bryskier A, Devallois A. In vitro activities of levofloxacin used alone and in combination with first- and second-line antituberculous drugs against Mycobacterium tuberculosis. Antimicrob Agents Chemother 1996;40:1610-6.
34. Rastogi N, Goh KS, Bryskier A, Devallois A. Spectrum of activity of levofloxacin against nontuberculous mycobacteria and its activity against the Mycobacterium avium complex in combination with ethambutol, rifampin, roxithromycin, amikacin, and clofazimine. Antimicrob Agents Chemother 1996;40:2483-7.
35. Sbarbaro JA, Iseman MD, Crowle A. Combined effect of pyrazinamide and ofloxacin within the human macrophage. Tuberc Lug Dis 1996;77:491-5.
36. Hoffner SE, Gezelius L, Olsson-Liljequist B. In-vitro activity of fiuorinated quinolones and macrolides against drug-resistant Mycobacterium tuberculosis. J Antimicrob Chemother 1997;40:885-8.
37. Zhao BY, Pine R, Domagala J, Drlica K. Fluoroquinolone action against clinical isolates of Mycobacterium tuberculosis: effects of a C-8 methoxy group on survival in liquid media and in human macrophages. Antimicrob Agents Chemother 1999;43:661-6.
38. Takahata M, Mitsuyama J, Yamashiro Y, Yonezawa M, Araki H, Todo Y, et al. In vitro and in vivo antimicrobial activities of T-3811ME, a novel Des-F(6)-quinolone. Antimicrob Agents Chemother 1999;43:1077-84.
39. Tomioka H, Sato K, Kajitani H, Akaki T, Shishido S. Comparative antimicrobial activities of a newly synthesized quinolone WQ-3034, levofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterum tuberculosis and Mycobacterium avium complex. Antimicrob Agents Chemother. In press 2000.
40. Yajko DM, Sanders CA, Madej JJ, Cawthon VL, Hadley WK. In vitro activities of rifabutin, azithromycin, ciprofloxacin, clarithromycin, clofazimine, ethambutol, and amikacin in combinations of two, three, and four drugs against Mycobacterium avium. Antimicrob Agents Chemother 1996;40:743-9.
41. Truffot-Pernot C, Ji B, Grosset J. Activities of pefloxacin and ofloxacin against mycobacteria: in vitro and mouse experiments. Tubercle 1991;72:57-64.
42. Miyazaki E, Miyazaki M, Chen JM, Caisson RE, Bishal WR. Moxifloxacin (BAY 12-8039), a new 8-methoxyquinolone, is active in a mouse model of tuberculosis. Antimicrob Agents Chemother 1999;43:85-9.
43. Heifets L. Clarithromycin against Mycobacterium avium complex infection. Tuberc Lung Dis 1996;77:19-26.
44. Amsden GW, Peloquin CA, Berning SE. The role of advanced generation macrolides in the prophylaxis and treatment of Mycobacterium avium complex (MAC) infections. Drugs 1997;54:69-80.
45. Fernandes PB, Hardy DJ, MacDaniel D, Hanson CW, Swanson RN. In vitro and in vivo activities of clarithromycin against Mycobacterium avium. Antimicrob Agents Chemother 1989;33:1531-4.
46. Naik S, Ruck R. In vitro activities of several new macrolide antibiotics against Mycobacterium avium complex. Antimicrob Agents Chemother 1989;33:1614-6.
47. Perronne C, Gikas A, Truffot-Pernot C, Grosset J, Vilde J-L, Pocidalo J-J. Activities of sperfloxacin, azithromycin, temafloxacin, and rifapentine compared with that of clarithromycin against multiplication of Mycobacterium avium complex within human macrophages. Antimicrob Agents Chemother 1991;35: 1356-9.
48. Brown BA, Wallace RJ Jr, Onyi GO, De Rosas V, Wallace RJ. Activities of four macrolides including clarithromycin, against Mycobacterium fortuitum, Mycobacterium chelonae, and M. clielonae-like organisms. Antimicrob Agents Chemother 1992;36: 180-4.
49. Heifets LB, Lindholm-Levy P, Comostock RD. Clarithromycin minimal inhibitory and bactericidal concentrations against Mycobacterium avium. Am Rev Respir Dis 1992;145:856-8.
50. Heifets LB, Lindholm-Levy P, Comstock RD. Bacteriostatic and bactericidal activities of gentamicin alone and in combination with clarithromycin against Mycobacterium avium. Antimicrob Agents Chemother 1992;36:1695-8.
51. Brown BA, Wallace RJ, Onyi GO. Activities of clarithromycin against slowly growing species of nontuberculous mycobacteria, determined by using a broth microdilution MIC system. Antimicrob Agents Chemother 1992;36:1987-90.
52. Saito H, Tomioka H, Sato K, Dekio S. In vitro and in vivo activities of clarithromycin against the Mycobacterium avium complex. Int J Antimicrob Agents 1994;4:175-81.
53. Rastogi N, Goh KS, Bryskier A. Activities of roxithromycin used alone and in combination with ethambutol, rifampin, amikacin, ofloxacin, and clofazimine against Mycobacterium avium complex. Antimicrob Agents Chemother 1994;38:1433-8.
54. Fattorini L, Li B, Piersimoni C, Tortoli E, Xiao Y, Santoro C, et al. In vitro and ex vivo activities of antimicrobial agents used in combination with clarithromycin, with or without amikacin, against Mycobacterium avium. Antimicrob Agents Chemother 1995;39:680-5.
55. Rastogi N, Labrousse V, Bryskier A. Intracellular activities of roxithromycin used alone and in association with other drugs against Mycobacterium avium complex in human macrophages. Antimicrob Agents Chemother 1995;39:976-8.
56. Rastogi N, Goh KS, Ruiz P, Casal M. In vitro activity of roxithromycin against the Mycobacterium tuberculosis complex. Antimicrob Agents Chemother 1995;39:1162-5.
57. Cavalieri SJ, Biehle JR, Sanders WE. Synergistic activities of clarithromycin and antituberculous drugs against multidrug-resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother 1995;39:1542-5.
58. Truffot-Pernot C, Lounis N, Grosset JH, Ji B. Clarithromycin is inactive against Mycobacterium tuberculosis. Antimicrob Agents Chemother 1995;39:2827-8.
59. Pellegrin I, Maugein J, Lapeyre C, Barbeau P, Leng B, Pellegrin J-L. Activity of rifabutin, clarithromycin, ethambutol, sparfloxacin and amikacin, alone and in combination, against Mycobacterium avium in human macrophages. J Antimicrob Chemother 1996;37:501-10.
60. Sato K, Akaki T, Tomioka H. Antimicrobial activities of benzoxazinorifamycin KRM-1648, clarithromycin and levofloxacin against intracellualr Mycobacterium avium complex phagocytosed by murine peritoneal macrophages. J Antimicrob Chemother 1998;41:77-83.
61. Sato K, Tomioka H. Antimicrobial activities of benzoxazino-rifamycin (KRM-1648) and clarithromycin against Mycobacterium avium-intracellulare complex within murine peritoneal macrophages, human macrophage-like cells and human alveolar epithelial cells. J Antimicrob Chemother 1999;43:351-7.
62. Cynamon MH, Klemens SP. Activity of azithromycin against Mycobacterium avium infection in beige mice. Antimicrob Agents Chemother 1992;36:1611-3.
63. Klemens SP, DeStefano MS, Cynamon MH. Activity of clarithromycin against Mycobacterium avium complex infection in beige mice. Antimicrob Agents Chemother 1992;36:2413-7.
64. Cynamon MH, Klemens SP, Grossi MA. Comparative activities of azithromycin against Mycobacterium avium infection in beige mice. Antimicrob Agents Chemother 2994;38:1452-4.
65. Klemens SP, Cynamon MH. Activities of azithromycin and clarithromycin against nontuberculous mycobacteria in beige mice. Antimicrob Agents Chemother 1994;38:1455-9.
66. Klemens SP, Cynamon MH. Intermittent azithromycin for treatment of Mycobacterium avium infection in beige mice. Antimicrob Agents Chemother 1994;38:1721-5.
67. Ji B, Lounis N, Truffot-Pernot C, Grosset J. Effectiveness of various antimicrobial agents against Mycobacterium avium complex in the beige mouse model. Antimicrob Agents Chemother 1994;38:2521-9.
68. Bermudez LE, Inderlied CB, Kolonoski P, Petrofsky M, Young LS. Clarithromycin, dapson, and a combination of both used to treat or prevent disseminated Mycobacterium avium infection in beige mice. Antimicrob Agents Chemother 1994;38:2717-21.
69. Struillou L, Cohen Y, Lounis N, Bertrand G, Grosset J, Vilde J-L, et al. Activities of roxithromycin against Mycobacterium avium infections in human macrophages and C57BL/6 mice. Antimicrob Agents Chemother 1995;39:878-81.
70. Bermudez LE, Kolonoski P, Young LS. Roxithromycin alone and in combination with ethambutol or levofloxacin for disseminated Mycobacterium avium infections in beige mice. Antimicrob Agents Chemother 1996;40:1033-5.
71. Lounis N, Ji B, Truffot-Pernot C, Grosset J. Comparative activities of amikacin against Mycobacterium avium complex in nude and beige mice. Antimicrob Agents Chemother 1997;41:1168-9.
72. Fattorini L, Xiao Y, Mattei M, Li Y, Iona E, Ricci ML, et al. Activities of isoniazid alone and in combination with other drugs against Mycobacterium avium infection in beige mice. Antimicrob Agents Chemother 1998;42:712-4.
73. Dautzenberg B, Truffot C, Legris S, Meyohas MC, Berlie HC, Mercat A, et al. Activity of clarithromycin against Mycobacterium avium infection in patients with the acquired immune deficiency syndrome. A controlled clinical trial. Am Rev Respir Dis 1991; 144:564-9.
74. Young LS, Wiviott L, Wu M, Kolonoski P, Bolan R, Inderlied CB. Azithromycin for treatment of Mycobacterium avium-intracellulare complex infection in patients with AIDS. Lancet 1991;338:1107-9.
75. Dautzenberg B, Saint Marc T, Meyohas MC, Eliazewitch M, Haniez F, Rogues AM, et al. Clarithromycin and other antimycobacterial agents in the treatment of disseminated Mycobacterium avium infections in patients with acquired immunodeficiency syndrome. Arch Intern Med 1993;153:368-72.
76. Chaisson RE, Benson CA, Dube MP, Heifets LB, Korvick JA, Elkin S, et al. Clarithromycin therapy for bacteremic Mycobacterium avium complex disease. A randomized, double-blind, dose-ranging study in patients with AIDS. Ann Intern Med 1994; 121:905-11.
77. Wallace RJ, Brown BA, Griffith DE, Girard WM, Murphy DT. Clarithromycin regimens for pulmonary Mycobacterium avium complex. The first 50 patients. Am J Respir Crit Care Med 1996;153:1766-72.
78. Yamamoto M, Kuze F, Saito H, Sakatani M, Shimoide H, Soejima R, et al. The clinical study of clarithromycin for pulmonary Mycobacterium avium-intracellulare complex infection. Kekkaku 1997;72:1-7.
79. Amsden GW, Peloquin CA, Berning SE. The role of advanced generation macrolides in the prophylaxis and treatment of Mycobacterium avium complex (MAC) infections. Drugs 1997;54:69-80.
80. American Thoracic Society. Diagnosis and treatment of diseases caused by nontuberculous mycobacteria. Am J Respir Crit Care Med 1997;156:S1-25.
81. Mangura BT, Reichman LB. Prevention and treatment of Mycobacterium avium complex infection. Res Microbiol 1994;145:181-7.
82. Pierce M, Crampton S, Henry D, Heifets L, LaMarca A, Montecalvo M, et al. A randomized trial of clarithromycin as prophylaxis against disseminated Mycobacteriiu avium complex infection in patients with advanced acquired immunodeficiency syndrome. New Engl J Med 1996;335:384-91.
83. Havlir DV, Dube MP, Sattler FR, Forthal DN, Kemper CA, Dünne MW, et al. Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both. New Engl J Med 1996;335:392-8.
84. Dautzenberg B. Rationale for the prevention of disseminated Mycobacterium avium complex disease. Drugs 1997;54(Suppl 2):1-7.
85. Traxler P, Vischer WA, Zak O. New rifamycins. Drugs of the Future 1988;13:845-56.
86. Kunin CM. Antimicrobial activity of rifabutin. Clin Infect Dis 1996;22(Suppl 1):S3-14.
87. Tomioka H, Sato K, Hidaka T, Saito H. In vitro and in vivo antimycobacterial activities of KRM-1648, a new benzoxazinorifamycin. In: Pandali SG, editor. Recent research developments in antimicrobial agents and chemotherapy Trivandrum: Research Signpost; 1997. p.37-68.
88. O'Brien RJ, Lyle MA, Snider DE. Rifabutin (Ansamycin LM 427): a new rifamycin-S derivative for the treatment of mycobacterial diseases. Rev Infect Dis 1987;9:519-30.
89. Sullam PM. Rifabutin therapy for disseminated Mycobacterium avium complex infection. Clin Infect Dis 1996;22(Suppl 1):S37-42.
90. Grassi C, Peona V. Use of rifabutin in the treatment of pulmonary tuberculosis. Clin Infect Dis 1996;22(Suppl 1):S50-4.
91. Brogden RN, Fitton A. Rifabutin: a review of its antimicrobial activity, pharmacokinetic properties and therapeutic efficacy. Drugs 1994;47:983-1009.
92. Chaisson RE. Potential role of rifabutin in prophylaxis for tuberculosis and infections due to multiple opportunistic pathogens. Clin Infect Dis 1996;22(Suppl 1):S61-9.
93. Carosi G, Matteelli A. Prophylaxis for tuberculosis in Europe - ongoing research. Clin Infect Dis 1996;22(Suppl 1):S55-60.
94. Heifets LB, Iseman MD. Determination of in vitro susceptibility of mycobacteria to ansamycin. Am Rev Respir Dis 1985;132:710-1.
95. Dickinson JM, Mitchinson DA. In vitro properties of rifapentine (MDL473) relevant to its use in intermittent chemotherapy of tuberculosis. Tubercle 1987;68:113-8.
96. Heifets LB, Lindholm-Levy PJ, Iseman MD. Rifabutin: minimal inhibitory and bactericidal concentrations for Mycobacterium tuberculosis. Am Rev Respir Dis 1988;137:719-21.
97. Saito H, Sato K, Tomioka H. Comparative in vitro and in vivo activity of rifabutin and rifampicin against Mycobacterium avium complex. Tubercle 1988;69:187-92.
98. Heifets LB, Lindholm-Levy PJ, Flory MA. Bactericidal activity in vitro of various rifamycins against Mycobacterium avium and Mycobacterium tuberculosis. Am Rev Respir Dis 1990;141:626-30.
99. Dhillon J, Mitchison DA. Activity of rifabutin, FCE 22807, rifapentine, and rifampin against Mycobacterium microti and Mycobacterium tuberculosis and their penetration into mouse peritoneal macrophages. Am Rev Respir Dis 1992;145:212-4.
100. Heifets LB, Iseman MD, Lindholm-Levy PJ. Combinations of rifampin or rifabutin plus ethambutol against Mycobacterium avium complex. Bactericidal synergistic, and bacteriostatic additive or synergistic effects. Am Rev Respir Dis 1988;137:711-5.
101. Casal M, Rodriguez F, Villalba R, Gonzalez AI. In vitro susceptibility of Mycobacterium avium-complex against rifabutin (LM427) alone and in combination with amikacin, roxithromycin and ethambutol. Rev Esp Quimioterap 1990;3:87-9.
102. Gangadharam PRJ, Perumal VK, Jairam BT, Rao PN, Nguyen AK, Farhi DC, et al. Activity of rifabutin alone or in combination with clofazimine or ethambutol or both against acute and chronic experimental Mycobacterium intracellulare infections. Am Rev Respir Dis 1987;136:329-33.
103. Furney SK, Roberts AD, Orme IM. Effect of rifabutin on disseminated Mycobacterium avium infections in thymectomized, CD4 T-cell-deficient mice. Antimicrob Agents Chemother 1990;34:1629-32.
104. Klemens SP, Cynamon MH. In vivo activities of newer rifamycin analogs against Mycobacterium avium infection. Antimicrob Agents Chemother 1991;35:2026-30.
105. Lazard T, Perronne C, Grosset J, Vilde JL, Pocidalo JJ. Clarithromycin, minocycline, and rifabutin treatments before and after infection of C57BL/6 mice with Mycobacterium avium. Antimicrob Agents Chemother 1993;37:1690-2.
106. Klemens SP, Grossi MA, Cynamon MH. Comparative in vivo activities of rifabutin and rifapentine against Mycobacterium avium complex. Antimicrob Agents Chemother 1994;38:234-7.
107. Jabes D, Della Bruna C, Rossi R, Olliaro P. Effectiveness of rifabutin alone or in combination with isoniazid in the preventive therapy of mouse tuberculosis. Antimicrob Agents Chemother 1994;38:2346-50.
108. Lenaerts AMJA, Chase SE, Chmielewski AJ, Cynamon MH. Evaluation of rifapentine in long-term treatment regimens for tuberculosis in mice. Antimicrob Agents Chemother 1999;43: 2356-60.
109. Gonzalez-Montaner LJ, Natal S, Yongchaiyud P, Olliaro P, the Rifabutin Study Group. Rifabutin for the treatment of newly diagnosed pulmonary tuberculosis: a multinational, randomized, comparative study versus rifampicin. Tuberc Lung Dis 1994; 75:341-7.
110. Dautzenberg B, Castellani P, Pellegrin J, Vittecoq D, Truffot-Pernot C, Pirotta N, et al. Early bactericidal activity of rifabutin versus that of placebo in treatment of disseminated Mycobacterium avium complex bacteremia in AIDS patients. Antimicrob Agents Chemother 1996;40:1722-5.
111. Masur H, Tuazon C, Gill V, Grimes G, Baird B, Fauci AS, et al. Effect of combined clofazimine and ansamycin therapy on Mycobacterium avium-Mycobacterium intracellulare bacteremia in patients with AIDS. J Infect Dis 1987;155:127-9.
112. Agins BD, Berman DS, Spicehandler D, El-Sadr W, Simberkoff MS, Rahal JJ. Effect of combined therapy with ansamycin, clofazimine, ethambutol, and isoniazid for Mycobacterium avium infection in patients with AIDS. J Infect Dis 1989;159:784-7.
113. Hoy J, Mijch A, Sandland M, Grayson L, Lucas R, Dwyer B. Quadruple-drug therapy for Mycobacterium avium-intracellulare bacteremia in AIDS patients. J Infect Dis 1990;161:801-5.
114. Dautzenberg B, Truffot C, Mignon A, Rozenbaum W, Katlama C, Perronne C, et al. Rifabutin in combination with clofazimine, isoniazid and ethambutol in the treatment of AIDS patients with infections due to opportunistic mycobacteria. Tubercle 1991;72: 168-75.
115. Shafran SD, Singer J, Zarowny DP, Phillips P, Salt I, Walmsley SL, et al. A comparison of two regimens for the treatment of Mycobacterium avium complex bacteremia in AIDS: rifabutin, ethambutol, and Clarithromycin versus rifampin, ethambutol, clofazimine, and ciprofloxacin. N Engl J Med 1996;335:377-83.
116. Yamane T, Hashizume T, Yamashita K, Konishi E, Hosoe K, Hidaka T, et al. Synthesis and biological activity of 3′-hydroxy-5′-aminobenzoxazinorifamycin derivatives. Chem Pharm Bull 1993; 41:148-55.
117. Saito H, Tomioka H, Sato K, Emori M, Yamane T, Yamashita K, et al. In vitro antimycobacterial activity of newly synthesized benzoxazinorifamycins. Antimicrob Agents Chemother 1991;35: 542-7.
118. Tomioka H, Saito H, Fujii K, Sato K, Hidaka T. In vitro antimicrobial activity of benzoxazinorifamycin, KRM-1648, against Mycobacterium avium complex determined by radiometric method. Antimicrob Agents Chemother 1993;37:67-70.
119. Inderlied CB, Barbara-Burnham L, Wu M, Young LS, Bermudez LM. Activities of the benzoxazinorifamycin KRM 1648 and ethambutol against Mycobacterium avium complex in vitro and in macrophages. Antimicrob Agents Chemother 1994;38:1838-43.
120. Luna-Herrera J, Reddy MV, Gangadharam PRJ. In vitro activity of benzoxazinorifamycin KRM-1648 against drug-susceptible and multidrug-resistant tubercle bacilli. Antimicrob Agents Chemother 1995;39:440-4.
121. Hirata T, Saito H, Tomioka H, Sato K, Jido J, Hosoe K. et al. In vitro and in vivo activities of the benzoxazinorifamycin KRM-1648 against Mycobacterium tuberculosis. Antimicrob Agents Chemother 1995;39:2295-303.
122. Mor N, Simon B, Heifets L. Bacteriostatic and bactericidal activities of benzoxazinorifamycin KRM-1648 against Mycobacterium tuberculosis and Mycobacterium avium in human macrophages. Antimicrob Agents Chemother 1996;40:1482-5.
123. Dhople AM, Dhople AA, Ibanez MA. Comparative in vitro activities of rifamycin analogues against rifampin-sensitive and rifampin-resistant Mycobacterium tuberculosis. Int J Antimicrob Agents 1997;8:209-14.
124. Fujii K, Saito H, Tomioka H, Mae T, Hosoe K. Mechanism of action of antimycobacterial activity of the new benzoxazinorifamycin KRM-1648. Antimicrob Agents Chemother 1995;39: 1489-92.
125. Telenti A, Imboden P, Marchesi F, Lowrie D, Cole S, Colston MJ, et al. Detection of rifampicin-resistant mutations in Mycobacterium tuberculosis. Lancet 1993;341:647-50.
126. Williams DL, Waguespack C, Eisenach K, Crawford JT, Portaels F, Salfinger M, et al. Characterization of rifampin resistance in pathogenic mycobacteria. Antimicrob Agents Chemother 1994; 38:2380-6.
127. Moghazeh SL, Pan X, Arain T, Stover CK, Musser JM, Kreiswirth BN. Comparative antimycobacterial activities of rifampin, rifapentine, and KRM-1648 against a collection of rifampin-resistant Mycobacterium tuberculosis isolates with known rpoB mutations. Antimicrob Agents Chemother 1996;40:2655-7.
128. Bodmer T, Zurchner G, Imboden P, Telenti A. Mutation position and type of substitution in the β-subunit of the RNA polymerase influence in-vitro activity of rifamycin-resistant Mycobacterium tuberculosis. J Antimicrob Chemother 1995;35:345-8.
129. Sato K, Ogasawara K, Akaki T, Tomioka H. MICs and MBCs of levofloxacin, clarithromycin, and KRM-1648 for Mycobacterium tuberculosis and M. avium complex residing in Mono-Mac-6 human macrophage-like cell and A-549 human type II alveolar epithelial cell lines. Kekkaku 1999;74:571-7.
130. Hosoe K, Mae T, Konishi E, Fujii K, Yamashita K, Yamane T, et al. Pharmacokinetics of KRM-1648, a new benzoxazinorifamycin, in rats and dogs. Antimicrob Agents Chemother 1996;40:2749-55.
131. Tomioka H, Saito H, Sato K, Yamane T, Yamashita K, Hosoe K, et al. Chemotherapeutic efficacy of a newly synthesized benzoxazinorifamycin, KRM-1648, against Mycobacterium avium complex infection induced in mice. Antimicrob Agents Chemother 1992;36:387-93.
132. Emori M, Saito H, Sato K, Tomioka H, Setogawa T, Hidaka T. Therapeutic efficacy of the benzoxazinorifamycin, KRM-1648, against experimental Mycobacterium avium infection induced in rabbits. Antimicrob Agents Chemother 1993;37:722-8.
133. Klemens SP, Grossi MA, Cynamon MH. Activity of KRM-1648, a new benzoxazinorifamycin, against Mycobacterium tuberculosis in a murine model. Antimicrob Agents Chemother 1994;38:2245-8.
134. Yamamoto T, Amitani R, Suzuki K, Tanaka E, Murayama T, Kuze F. In vitro bactericidal and in vivo therapeutic activities of a new rifamycin derivative, KRM-1648, against Mycobacterium tuberculosis. Antimicrob Agents Chemother 1996;40:426-8.
135. Reddy MV, Luna-Herrera J, Daneluzzi D, Gangadharam PRJ. Chemotherapeutic activity of benzoxazinorifamycin, KRM-1648, against Mycobacterium tuberculosis. Tuberc Lung Dis 1996;77:154-9.
136. Kelly BP, Furney SK, Jessen MT, Orme IM. Low-dose aerosol infection model for testing drugs for efficacy against Mycobacterium tuberculosis. Antimicrob Agents Chemother 1996;40:2809-12.
137. Tomioka H, Sato K, Shimizu T, Sano C, Akaki T, Saito H, et al. Effects of benzoxazinorifamycin KRM-1648 on cytokine production at sites of Mycobacterium avium complex infection induced in mice. Antimicrob Agents Chemother 1997;41:357-62.
138. Emori M, Tomioka H, Sato K, Saito H. Evaluation of in vivo therapeutic efficacy of a new benzoxazinorifamycin, KRM-1648, in SCID mouse model for disseminated Mycobacterium avium complex infection. Int J Antimicrob Agents 1998;10:59-65.
139. Klemens SP, Cynamon MH. Activity of KRM-1648 in combination with isoniazid against Mycobacterium tuberculosis in a murine model. Antimicrob Agents Chemother 1996;40:298-301.
140. Bermudez LE, Kolonoski P, Young LS, Inderlied CB. Activity of KRM-1648 alone or in combination with ethambutol or clarithromycin against Mycobacterium avium in beige mouse model of disseminated infection. Antimicrob Agents Chemother 1994;38:1844-8.
141. Saito H, Tomioka H, Sato K, Kawahara S, Hidaka T, Dekio S. Therapeutic effect of KRM-1648 with various antimicrobials against Mycobacterium avium complex infection in mice. Tuberc Lung Dis 1995;76:51-8.
142. Yamamoto T, Amitani R, Suzuki K, Tanaka E, Murayama T, Kuze F. Activity of KRM-1648 alone or in combination with both ethambutol and kanamycin or clarithromycin against Mycobacterium intracellulare infections in beige mice. Antimicrob Agents Chemother 1996;40:429-32.
143. Shimizu T, Tomioka H, Sato K, Sano C, Yamada Y, Shibata H. Effects of Yokuinin on the therapeutic efficacy of a new benzoxazinorifamycin KRM-1648 against Mycobacterium avium infection. Int J Antimicrob Agents 1999;11:69-74.
144. Sano C, Shimizu T, Sato K, Kawauchi H, Kawahara S, Tomioka H. Therapeutic effects of benzoxazinorifamycin KRM-1648 administered alone or in combination with a half-sized secretory leukocyte protease inhibitor or the nonsteroidal anti-inflammatory drug diclofenac sodium against Mycobacterium avium complex infection in mice. Antimicrob Agents Chemother 1999;43:360-4.
145. Shimizu T, Tomioka H, Sato K, Sano C, Akaki T. Dekio S, et al. Effects of the Chinese traditional medicine Mao-Bushi-Saishin-To on therapeutic efficacy of a new benzoxazinorifamycin, KRM-1648, against Mycobacterium avium infection in mice. Antimicrob Agents Chemother 1999;43:514-9.
146. Oleksijew A, Meulbroek J, Ewing P, Jarvis K, Mitten M, Paige L, et al. In vivo efficacy of ABT-255 against drug-sensitive and -resistant Mycobacterium tuberculosis strains. Antimicrob Agents Chemother 1998;42:2674-7.
147. Bermudez LE, Kolonoski P, Wu M, Aralar PA, Inderlied CB, Young LS. Mefloquine is active in vitro and in vivo against Mycobacterium avium complex. Antimicrob Agents Chemother 1999; 43:1870-4.
148. Sun Z, Zhang Y. Antituberculosis activity of certain antifungal and antihelmintic drugs. Tuberc Lung Dis 1999;79:319-20.